Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Cardio-Rheumatology: Cardiovascular Complications in Systemic Autoimmune Rheumatic Diseases / Is Inflammation the Common Link and Target?

Author(s): Antonis S. Manolis* and Athanasios G. Tzioufas

Volume 18, Issue 5, 2020

Page: [425 - 430] Pages: 6

DOI: 10.2174/1570161118666200514222236

Abstract

In the current Thematic Issue of Current Vascular Pharmacology (CVP), entitled “Systemic Autoimmune Rheumatic Diseases and Cardiology”, presented in two parts, Part 1 and Part 2, review articles are included from specialists in cardiology, rheumatology, immunology and related fields. These reviews discuss the cardiovascular complications of the main systemic Autoimmune Rheumatic Diseases (ARDs). For example, the underlying pathogenetic mechanisms, the role of cardiovascular imaging and recommendations for prevention and management. These articles place inflammation as the key process, linking cardiovascular complications with ARDs. From all these reviews, the conclusion is the need for collaboration between the disciplines of Rheumatology and Cardiology to establish the emerging field of Cardio- Rheumatology. This will aid to fine-tune risk stratification and optimize preventive strategies and pharmacological therapies for patients with ARDs.

Keywords: Autoimmune rheumatic disease, cardiovascular disease, cardiorheumatology, rheumatoid arthritis, systemic lupus erythematosus, Sjogren’s disease, spondyloarthropathies, systemic sclerosis, psoriasis, psoriatic arthritis, vasculitis, antirheumatic drugs, cardiovascular imaging, coronary artery disease, acute coronary syndromes, atherosclerosis, myocardial infarction, stroke.

Next »
[1]
England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ 2018; 361: k1036.
[http://dx.doi.org/10.1136/bmj.k1036] [PMID: 29685876]
[2]
Lee KS, Kronbichler A, Eisenhut M, Lee KH, Shin JI. Cardiovascular involvement in systemic rheumatic diseases: An integrated view for the treating physicians. Autoimmun Rev 2018; 17(3): 201-14.
[http://dx.doi.org/10.1016/j.autrev.2017.12.001] [PMID: 29353099]
[3]
Mankad R. Atherosclerotic vascular disease in the autoimmune rheumatologic patient. Curr Atheroscler Rep 2015; 17(4): 497.
[http://dx.doi.org/10.1007/s11883-015-0497-6] [PMID: 25721102]
[4]
Melissaropoulos K, Bogdanos D, Dimitroulas T, Sakkas LI, Kitas GD, Daoussis D. Primary Sjögren’s syndrome and cardiovascular disease. Curr Vasc Pharmacol 2020; 18(5): 447-54.
[http://dx.doi.org/10.2174/1570161118666200129125320] [PMID: 31995009]
[5]
Kostopoulou M, Nikolopoulos D, Parodis I, Bertsias G. Cardiovascular disease in systemic lupus erythematosus: recent data on epidemiology, risk factors and prevention. Curr Vasc Pharmacol 2019. Epub ahead of print
[http://dx.doi.org/10.2174/1570161118666191227101636] [PMID: 31880245]
[6]
Papagoras C, Voulgari P, Drosos A. Cardiovascular disease in spondyloarthritides. Curr Vasc Pharmacol 2020; 18(5): 473-87.
[http://dx.doi.org/10.2174/1570161117666190426164306]] [PMID: 31330576]
[7]
Fragoulis GE, Panayotidis I, Nikiphorou E. Cardiovascular risk in rheumatoid arthritis and mechanistic links: from pathophysiology to treatment. Curr Vasc Pharmacol 2020; 18(5): 431-46.
[http://dx.doi.org/10.2174/1570161117666190619143842] [PMID: 31258091]
[8]
Stea EA, Routsias JG, Clancy RM, Buyon JP, Moutsopoulos HM, Tzioufas AG. Anti-La/SSB antiidiotypic antibodies in maternal serum: a marker of low risk for neonatal lupus in an offspring. Arthritis Rheum 2006; 54(7): 2228-34.
[http://dx.doi.org/10.1002/art.21954] [PMID: 16802359]
[9]
Manolis AA, Manolis TA, Melita H, Manolis AS. Congenital heart block: Pace earlier (Childhood) than later (Adulthood). Trends Cardiovasc Med 2020; 30(5): 275-86.
[http://dx.doi.org/10.1016/j.tcm.2019.06.006.]
[10]
Taylor EB, Wolf VL, Dent E, Ryan MJ. Mechanisms of hypertension in autoimmune rheumatic diseases. Br J Pharmacol 2019; 176(12): 1897-913.
[http://dx.doi.org/10.1111/bph.14604] [PMID: 30714094]
[11]
Bartoloni E, Alunno A, Gerli R. Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases. Nat Rev Cardiol 2018; 15(1): 33-44.
[http://dx.doi.org/10.1038/nrcardio.2017.118] [PMID: 28836617]
[12]
Atzeni F, Nucera V, Gerratana E, et al. Cardiovascular consequences of autoimmune rheumatic diseases. Curr Vasc Pharmacol 2019. Epub ahead of print
[http://dx.doi.org/10.2174/1570161118666200127142936] [PMID: 31985379]
[13]
Van der Heiden K, Cuhlmann S, Luong A, Zakkar M, Evans PC. Role of nuclear factor kappaB in cardiovascular health and disease. Clin Sci 2010; 118(10): 593-605.
[http://dx.doi.org/10.1042/CS20090557] [PMID: 20175746]
[14]
van Loo G, Beyaert R. Negative regulation of NF-κB and its involvement in rheumatoid arthritis. Arthritis Res Ther 2011; 13(3): 221.
[http://dx.doi.org/10.1186/ar3324] [PMID: 21639951]
[15]
Brown KD, Claudio E, Siebenlist U. The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther 2008; 10(4): 212.
[http://dx.doi.org/10.1186/ar2457] [PMID: 18771589]
[16]
Mourouzis IS, Manolis AS, Pantos C. Cardiovascular risk of synthetic, non-biologic disease-modifying anti-rheumatic drugs (DMARDs). Curr Vasc Pharmacol 2020; 18(5): 455-62.
[http://dx.doi.org/10.2174/1570161117666190930113837] [PMID: 31566134]
[17]
Drakopoulou M, Soulaidopoulos S, Oikonomou G, Toutouzas K, Tousoulis D. Cardiovascular effects of biologic disease-modifying anti-rheumatic drugs (DMARDs). Curr Vasc Pharmacol 2020; 18(5): 488-506.
[http://dx.doi.org/10.2174/1570161118666200214115532] [PMID: 32056527]
[18]
Soulaidopoulos S, Madenidou AV, Daoussis D, et al. Cardiovascular disease in the Systemic Vasculitides. Curr Vasc Pharmacol 2020; 18(5): 463-72.
[http://dx.doi.org/10.2174/1570161118666200130093432] [PMID: 32000652]
[19]
Teixeira RA, Borba EF, Pedrosa A, et al. Evidence for cardiac safety and antiarrhythmic potential of chloroquine in systemic lupus erythematosus. Europace 2014; 16(6): 887-92.
[http://dx.doi.org/10.1093/europace/eut290] [PMID: 24050965]
[20]
Manolis AS, Manolis TA, Melita H. Atherosclerosis: an athero-thrombo-inflammatory disease. Hosp Chron 2012; 7: 195-201.
[21]
Manolis AA, Manolis TA, Melita H, Manolis AS. Psoriasis and cardiovascular disease: the elusive link. Int Rev Immunol 2019; 38(1): 33-54.
[http://dx.doi.org/10.1080/08830185.2018.1539084] [PMID: 30457023]
[22]
Kapniari E, Papadimitriou P, Dalamaga M, et al. Investigating the link between psoriasis and cardiovascular disease: current evidence, therapeutic implications and perspectives. Curr Vasc Pharmacol 2020. Epub ahead of print
[http://dx.doi.org/10.2174/1570161118666200523154318] [PMID: 32445456]
[23]
Polytarchou K, Varvarousis D, Manolis AS. Cardiovascular Disease in Antiphospholipid Syndrome. Curr Vasc Pharmacol 2019. Epub ahead of print
[http://dx.doi.org/10.2174/1570161117666190830101341] [PMID: 31530257]
[24]
Arsenaki E, Georgakopoulos P, Mitropoulou P, et al. Cardiovascular disease in Juvenile Idiopathic Arthritis. Curr Vasc Pharmacol 2020. Epub ahead of print
[http://dx.doi.org/10.2174/1570161118666200408121307] [PMID: 32268865]
[25]
Sule S, Fontaine K. Metabolic syndrome in adults with a history of juvenile arthritis. Open Access Rheumatol 2018; 10: 67-72.
[http://dx.doi.org/10.2147/OARRR.S157229] [PMID: 29922101]
[26]
Aulie HA, Estensen ME, Selvaag AM, Lilleby V, Flatø B, Aakhus S. Arterial properties in adults with long-lasting active juvenile idiopathic arthritis compared to healthy controls. Pediatr Rheumatol Online J 2018; 16(1): 85.
[http://dx.doi.org/10.1186/s12969-018-0302-5] [PMID: 30594204]
[27]
Sozeri B, Atikan BY, Ozdemir K, Mir S. Assessment of vascular function in systemic onset juvenile idiopathic arthritis. Clin Rheumatol 2016; 35(7): 1699-703.
[http://dx.doi.org/10.1007/s10067-016-3254-5] [PMID: 27075461]
[28]
Mani P, Uno K, Duong M, et al. HDL function and subclinical atherosclerosis in juvenile idiopathic arthritis. Cardiovasc Diagn Ther 2016; 6(1): 34-43.
[PMID: 26885490]
[29]
Evensen K, Aulie HA, Rønning OM, Flatø B, Russell D. Carotid atherosclerosis in adult patients with persistently active juvenile idiopathic arthritis compared with healthy controls. J Rheumatol 2016; 43(4): 810-5.
[http://dx.doi.org/10.3899/jrheum.150499] [PMID: 26879363]
[30]
Anderson JH, Anderson KR, Aulie HA, et al. Juvenile idiopathic arthritis and future risk for cardiovascular disease: a multicenter study. Scand J Rheumatol 2016; 45(4): 299-303.
[http://dx.doi.org/10.3109/03009742.2015.1126345] [PMID: 26854592]
[31]
Koca B, Sahin S, Adrovic A, Barut K, Kasapcopur O. Cardiac involvement in juvenile idiopathic arthritis. Rheumatol Int 2017; 37(1): 137-42.
[http://dx.doi.org/10.1007/s00296-016-3534-z] [PMID: 27417551]
[32]
Raab A, Sengler C, Niewerth M, et al. Comorbidity profiles among adult patients with juvenile idiopathic arthritis: results of a biologic register. Clin Exp Rheumatol 2013; 31(5): 796-802.
[PMID: 23557722]
[33]
Prasad M, Hermann J, Gabriel SE, et al. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol 2015; 12(3): 168-76.
[http://dx.doi.org/10.1038/nrcardio.2014.206] [PMID: 25533796]

Rights & Permissions Print Cite
Article Metrics
62
4
© 2024 Bentham Science Publishers | Privacy Policy